An observational study in Tobacco Smoke Pollution, Maternal Exposure During Pregnancy and Infant, Newborn, sponsored by Haseki Training and Research Hospital. Not yet recruiting. Open to participants aged 0 Minutes to 72 Hours, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-21.
Sponsored by Haseki Training and Research Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Prenatal exposure to tobacco smoke, through either active maternal smoking or secondhand exposure, has been associated with impaired fetal oxygenation, metabolic stress, and adverse early neonatal outcomes. This prospective, single-center observational cohort study will objectively assess maternal tobacco exposure using cotinine measured in maternal urine and examine its association with early neonatal biochemical, metabolic, and clinical outcomes.
Consecutive eligible mother-newborn dyads will be recruited at a tertiary academic hospital after written informed consent is obtained. A clean-catch midstream maternal urine sample will be collected within 24 hours before delivery, preferably at admission to the delivery unit and before intravenous fluid administration, for quantitative cotinine and creatinine measurement. Maternal tobacco exposure will be assessed using the urinary cotinine concentration, the cotinine-to-creatinine ratio, and maternal self-reported smoking and secondhand smoke exposure. Based on prespecified biomarker thresholds and exposure history, participants will be classified as having active exposure, passive exposure, or no exposure. No experimental intervention will be administered.
Neonatal data will include umbilical cord blood gas parameters, including pH, pCO2, pO2, base excess, bicarbonate, lactate, and fetal carboxyhemoglobin (FCOHb). Birthweight, length, head circumference, Apgar scores, oxygen saturation, heart rate, and blood pressure will also be recorded. Routine laboratory measurements obtained during the early postnatal period will include complete blood count parameters, hematologic and inflammatory indices such as NLR and PLR, albumin, the albumin-to-lactate ratio, HDL, LDL, and other routinely available biochemical markers. Thyroid-stimulating hormone results from the national newborn screening program and newborn hearing screening results will be recorded. Postnatal weight loss and bilirubin measurements from routine follow-up visits will also be collected when available.
The primary objective is to determine whether increasing maternal urinary cotinine exposure is associated with higher umbilical cord blood lactate and FCOHb levels, indicating greater metabolic stress and impaired fetal oxygenation. Secondary objectives include evaluating associations with cord blood gas parameters, birthweight, early hematologic and biochemical indices, albumin and the albumin-to-lactate ratio, blood pressure, bilirubin levels, thyroid screening results, and hearing screening outcomes.
Maternal, obstetric, and perinatal variables, including maternal age, parity, gestational age, mode of delivery, smoking history, intrapartum factors, and relevant maternal comorbidities, will be recorded for adjusted analyses. Statistical analyses will include comparisons among the three exposure groups and multivariable regression models evaluating urinary cotinine both as a continuous measure and as a categorical exposure variable.
This study is designed to provide prospectively collected, biomarker-verified evidence regarding the relationship between maternal tobacco exposure and immediate neonatal metabolic, hematologic, and physiologic outcomes using measurements that are feasible within routine clinical care.
44 studies on the registry are indexed under Carbon Monoxide Poisoning; 8 are open to participants now.
This study's planned enrollment of 126 is above the median of 104 across 25 observational studies indexed under Carbon Monoxide Poisoning.
Browse Carbon Monoxide Poisoning studies →Haseki Training and Research Hospital is the lead sponsor of 78 studies on the registry; 17 are open to participants now.
Counted across the registry records on this site, refreshed daily.
This is a single-center prospective cohort study conducted at a tertiary hospital. Consecutive eligible mother-newborn dyads are recruited during the delivery hospitalization. Maternal clean-catch urine is collected within 24 hours before delivery for cotinine and creatinine measurement. Dyads are classified as active exposure, passive exposure, or no exposure according to prespecified urinary cotinine-to-creatinine thresholds and maternal exposure history.
Outcomes are obtained mainly from routine care and include cord blood lactate, pH, base excess, FCOHb, birthweight, anthropometric measurements, Apgar scores, vital signs, early laboratory results, newborn screening TSH, hearing screening, and follow-up weight loss and bilirubin where available. No experimental intervention or additional neonatal blood sampling is planned.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Mother-newborn dyads in whom the maternal urinary cotinine-to-creatinine ratio is consistent with active tobacco exposure according to the prespecified study threshold. Maternal self-reported smoking and secondhand smoke exposure will also be recorded as supportive exposure information. Neonatal outcomes will include umbilical cord blood gas parameters, including pH, pCO2, pO2, base excess, bicarbonate, lactate, and fetal carboxyhemoglobin (FCOHb); birthweight and other anthropometric measurements; Apgar scores; oxygen saturation; heart rate; blood pressure; and routine laboratory measurements obtained during the early postnatal period. Laboratory variables will include complete blood count parameters, NLR, PLR, albumin, the albumin-to-lactate ratio, HDL, LDL, and other routinely available biochemical markers. Newborn screening TSH, hearing screening results, postnatal weight loss, and bilirubin measurements will also be recorded where available.
Other: Maternal Urinary Cotinine Assessment
Mother-newborn dyads in whom the maternal urinary cotinine-to-creatinine ratio is detectable but below the active-exposure threshold and is consistent with passive prenatal tobacco exposure according to the prespecified study thresholds. Maternal self-reported smoking and secondhand smoke exposure will also be recorded as supportive exposure information. The same neonatal biochemical, metabolic, physiologic, and clinical measurements will be collected as in the active-exposure and reference cohorts. No experimental intervention will be administered.
Other: Maternal Urinary Cotinine Assessment
Mother-newborn dyads in whom the maternal urinary cotinine-to-creatinine ratio is below the prespecified no-exposure threshold or below the analytical detection limit. Maternal smoking and secondhand smoke exposure history will also be recorded to assess agreement between biomarker-based and self-reported exposure classifications. The same neonatal biochemical, metabolic, physiologic, and clinical measurements will be collected as in the exposed cohorts. No experimental intervention will be administered.
Other: Maternal Urinary Cotinine Assessment
A clean-catch midstream maternal urine sample will be collected within 24 hours before delivery, preferably at admission to the delivery unit and before intravenous fluid administration. Urinary cotinine and creatinine concentrations will be measured, and the cotinine-to-creatinine ratio will be used to objectively classify prenatal tobacco exposure. No treatment or behavioral intervention will be assigned.
Umbilical Cord Blood Lactate
Umbilical cord blood lactate concentration measured using routine blood gas analysis. Lactate levels will be compared across maternal urinary cotinine-defined exposure groups (active, passive, and no exposure) and evaluated in multivariable regression models with adjustment for relevant maternal and perinatal factors. Unit of Measure: mmol/L.
Time frame: At birth (sample obtained within 10 minutes of delivery; analyzed within routine lab turnaround)
Umbilical Cord Blood pH
Arterial/venous cord blood pH per routine gas analysis; association with maternal cotinine exposure categories. Unit of Measure: pH units
Time frame: At birth (within 10 minutes)
Umbilical Cord Blood Base Excess (BE)
Base excess from routine cord gas; group comparisons and adjusted models parallel to primary analysis. Unit of Measure: mEq/L
Time frame: At birth (within 10 minutes)
Fetal Carboxyhemoglobin (FCOHb)
Percent carboxyhemoglobin from cord blood CO-oximetry; tested for dose-response with maternal urinary cotinine. Unit of Measure: percent
Time frame: At birth (same cord sample, routine CO-oximetry if available)
No study locations are listed for this record.
Start is estimated for Aug 2026; primary completion for Nov 2026, 3 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Haseki Training and Research Hospital